<DOC>
	<DOCNO>NCT02205151</DOCNO>
	<brief_summary>An Open-label , Randomized , Single-dose , 2×2 Crossover Study Compare Pharmacokinetics Fimasartan/Amlodipine Combination Tablet Coadministration Fimasartan Amlodipine Individual Tablets Healthy Male Volunteers</brief_summary>
	<brief_title>To Compare Pharmacokinetics Fimasartan/Amlodipine Combination Tablet Coadministration Fimasartan Amlodipine Individual Tablets</brief_title>
	<detailed_description>After subject sign informed consent voluntarily , go screening period within 21 day . As period I , subject A Group take fimasartan amlodipine 1st day subject B Group take fimasartan/amlodipine combination 1st day . And , wash 14 day , period II , subject A Group take fimasartan/amlodipine combination 15th day subject B Group take fimasartan amlodipine 15th day . At period , subject A Group blood sample 0 , 0.25 , 0.5 , 0.75 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 , 24 , 48 , 72 , 96 144 hour medication ( 18 time period , 36 time total ) . At period , subject B Group blood sample 0 , 0.25 , 0.5 , 0.75 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 , 24 , 48 , 72 , 96 144 hour medication ( 18 time period , 36 time total ) .</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Healthy male subject , age 19 50 year screen . 2 . Body weight ≥ 50 kg within ± 20 % ideal body weight ( IBW ) ( kg ) = { height ( cm ) 100 } * 0.9 3 . Subjects must able listen understand detailed statement inform consent , willing decide participate study , follow study direction provide write informed consent 1 . History gastrointestinal disease ( i.g. , Crohn 's disease , active peptic ulcer ) resection operation may affect absorption study drug ( exclude simple appendectomy herniorrhaphy ) 2 . History clinically significant hypersensitivity study drug , drug additive ( yellow no.4 ) . 3 . Subject judged inappropriate participate study base physical examination 4 . The level ALT ( Aspartate Transaminase ) , AST ( Alanin Transaminase ) total bilirubin &gt; 1.5 x upper limit normal eGFR &lt; 60 mL/min/1.73m ( calculated MDRD ) 5 . Evidence hereditary disease , include galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 6. systolic ≥ 140 mmHg ≤ 100 mmHg , diastolic ≥ 90 mmHg ≤ 65 mmHg ) , measure take rest 5minutes 7 . Take study 's investigational product within 90 day prior first administration study drug 8 . Donation whole blood within 60 day prior first administration study drug , donation blood product within 30 day prior first administration study drug 9 . Intake food like Grapefruit juice ( *e.g. , Grapefruit juice ≥ 1L /day ) within 7 day prior administration study drug 10 . Use prescribed drug herbal remedy within 14 day , use overthecounter medication vitamin within 7 day prior first administration study drug 11 . Positive serologic test ( HBsAg , HCV Ab , HIV Ag/Ab , VDRL ) 12 . Subject judged inappropriate participate study investigator , base reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>